Condiciones de salud que capsaicina puede ayudar a apoyar.
Capsaicin activates TRPV1 receptors in the GI tract and sensory nerves, triggering catecholamine release, stimulating GLP-1 and CCK, and suppressing ghrelin. Multiple RCTs demonstrate it reduces energy intake by approximately 74 kcal/meal and decreases appetite scores. A systematic review confirms consistent appetite-reduction effects across clinical studies at doses of 2–10 mg/day.
Capsaicin, the pungent compound in chili peppers, activates TRPV1 channels promoting NO production and vasodilation. A 2024 PMC vascular nutraceutical review explicitly listed capsaicin among nutraceuticals associated with greater endothelial function and decreased arterial stiffness. Multiple human studies show inverse associations between capsaicin/chili consumption and cardiovascular mortality.
Capsaicin, the pungent vanilloid compound from chili peppers, depletes substance P from sensory nerve endings via TRPV1 receptor activation, reducing arthritic joint pain. Multiple RCTs and a systematic review meta-analysis confirm topical capsaicin reduces OA pain, with the Cochrane evidence base supporting its use for hand OA particularly.
Capsaicin, the active vanilloid alkaloid of capsicum, is supported by multiple RCTs for topical treatment of chronic nonspecific low back pain. It acts via TRPV1 receptor activation, depleting substance P from nociceptors to produce lasting desensitization. Double-blind trials with capsaicin plasters or creams showed statistically significant pain reduction versus placebo (p=0.002) in populations with chronic LBP.
Capsaicin, the active compound in chili peppers, reduces pain by depleting substance P from sensory nerve terminals, blocking pain signal transmission. Podiatric specialists recommend capsaicin cream for topical bunion pain relief. A capsaicin derivative (vocacapsaicin/CA-008) was specifically tested in clinical trials of hallux valgus bunionectomy patients for post-surgical analgesia.
Capsaicin is explicitly cited for bursitis by PainScale as producing anti-inflammatory and analgesic effects. It depletes substance P from sensory neurons, reducing pain signal transmission. It is typically used topically or with other anti-inflammatory supplements. Multiple integrative pain management sources cite it for musculoskeletal and joint inflammatory conditions.
Capsaicin is identified in MDPI Cosmetics (2026) peer-reviewed review as a key bioactive compound for cellulite treatment via TRPV1 activation, promoting thermogenesis, lipolysis, and skin elasticity improvement. In vivo studies confirm 0.01% topical capsaicin increases dermal IGF-1 and skin elasticity; a human trial demonstrated capsaicin-based body cream as safe and effective for skin firming.
Capsaicin, the pungent compound in chili peppers, desensitizes TRPV1 nociceptors and depletes substance P. A 2016 Cochrane review of 14 RCTs (2,050 participants) found capsicum/capsaicin reduced chronic pain more than placebo, including for low back pain and neuropathic pain. It is FDA-cleared in an 8% patch form for postherpetic neuralgia.
Capsaicin, the active compound in cayenne pepper, promotes vasodilation via TRPV1 receptor activation, triggering release of nitric oxide and calcitonin gene-related peptide (CGRP), a potent peripheral vasodilator. Animal and mechanistic studies robustly support these effects; human data, though limited and mixed in scale, signal modest benefits for peripheral circulation, blood pressure, and platelet function. Traditionally used for millennia for poor circulation.
Topical capsaicin (0.025%) has been identified in dietary supplement reviews as having evidence for joint tenderness relief in FM. A review of dietary supplements for FM treatment noted topical capsaicin showed benefit for joint tenderness, though not for overall FM pain. The Arthritis Foundation notes many studies showing capsaicin effectively reduces pain from FM among other conditions. Capsaicin depletes substance P from sensory nerve endings, reducing nociceptive signaling.
Capsaicin combined with isoflavones was evaluated in a double-blind placebo-controlled clinical trial and found to significantly improve total hair count in patients with alopecia areata, androgenetic alopecia, and alopecia totalis. The mechanism involves capsaicin-induced increase in IGF-1 production by sensory nerves, which promotes follicle growth.
Capsaicin activates TRPV1 receptors to stimulate thermogenesis, increase energy expenditure by ~50 kcal/day, and reduce appetite. A systematic review and meta-analysis (British Journal of Nutrition) found capsaicin intake significantly reduced ad libitum energy intake, and a 12-week double-blind RCT found decreased percent body fat vs. placebo.
Intravesical capsaicin desensitizes TRPV1 receptors on bladder C-fiber afferents, inhibiting the micturition reflex. In a dual-center clinical study of 79 patients with intractable incontinence (mostly due to spinal cord disease), complete continence was achieved in 44% and satisfactory improvement in 36%. Bladder capacity nearly tripled in responders. Clinical benefit lasts 3–6 months per instillation.
Capsaicin has robust human clinical evidence supporting its role in boosting metabolism. It acts primarily via TRPV1 receptor activation, stimulating thermogenesis, increasing resting metabolic rate, and enhancing fat oxidation. A 2020 meta-analysis of 13 placebo-controlled trials found capsaicinoids significantly raised resting metabolic rate by ~34 kcal/day; however, the overall magnitude of these effects is modest.
Capsaicin stimulates TRPV1 receptors in the airway, acutely inducing watery mucus secretion to dilute and mobilize viscous phlegm, while repeated low-dose application desensitizes airway TRPV1, reducing neurogenic inflammation and excess mucus over time. Intranasal capsaicin spray preparations are used clinically for non-allergic rhinitis with mucus symptoms.
Capsaicin is the primary vanilloid alkaloid that selectively activates TRPV1 receptors on sensory C-fiber nerve terminals, producing defunctionalization and prolonged pain relief in neuropathic conditions. An 8% topical capsaicin patch is FDA-approved for peripheral neuropathic pain. Systematic reviews confirm efficacy in post-herpetic neuralgia, HIV neuropathy, and evidence in painful diabetic neuropathy.
Capsaicin, the active compound from chili peppers, acts on bladder TRPV1 (vanilloid) receptors on afferent nerves. Intravesical capsaicin instillation desensitizes C-fiber afferents, inhibiting the micturition reflex and increasing bladder capacity. It is reviewed in both the PMC Reviews in Urology (2013) and a 2024 PMC comprehensive OAB review as a recognized intervention for neurogenic detrusor overactivity; however, intravesical application causes local irritation, limiting use.
Capsaicin topical cream has been clinically evaluated for psoriasis, primarily for its ability to deplete substance P from skin nerve fibers, reducing itch and plaque severity. Clinical trials and reviews report significant itch reduction and some improvement in psoriatic severity scores. It is recognized as a topical botanical agent for psoriasis in systematic reviews.
Capsaicin, the active pungent compound in Capsicum peppers, acts on TRPV1 receptors on nociceptive fibers to desensitize pain signaling. Topical capsaicin is FDA-recognized as an OTC counterirritant for neuropathic pain and has been studied in sciatica-related neuropathic pain models. High-concentration capsaicin patch (8%) is used clinically for peripheral neuropathic pain.
Topical intranasal capsaicin is acknowledged by NCCIH as a studied approach for allergic rhinitis. Capsaicin desensitizes TRPV1 receptors on sensory neurons in the nasal mucosa, reducing neurogenic inflammation, sneezing, and rhinorrhea. Multiple clinical studies have evaluated intranasal capsaicin for non-allergic and allergic rhinitis.
Intranasal capsaicin desensitizes TRPV1 nociceptors on nasal sensory nerve endings, persistently reducing neurogenic inflammation, rhinorrhea, sneezing, and nasal congestion. Clinical studies document approximately 60% reduction in nasal airway resistance following intranasal application, with benefit lasting more than 4 months in most patients. It is particularly studied and effective for idiopathic non-allergic rhinitis where conventional antihistamines are ineffective.
Intranasal capsaicin is a recognized treatment option for non-allergic rhinitis, with multiple clinical trials and a Cochrane review confirming efficacy. It desensitizes TRPV1 receptors in nasal mucosa, reducing congestion, nasal pain, headache, and sinus pressure. Evidence is for rhinitis/sinus symptoms rather than infectious sinusitis per se.
Capsaicin, the active compound in chili peppers, is one of the most scientifically validated non-stimulant thermogenic agents. It increases energy expenditure by activating TRPV1 receptors, triggering catecholamine release, and shifting substrate oxidation toward fat. Meta-analyses confirm modest increases in resting energy expenditure and fat oxidation.
Capsaicin acts on TRPV1 receptors, initially activating then desensitizing nociceptive neurons, leading to pain relief. PMC 2022 review (University of Rome Tor Vergata) demonstrated effective topical capsaicin application in five patients with refractory oro-facial neuropathic pain. A 2025 PMC systematic review ranked capsaicin among the top phytotherapeutic analgesics for dental pain alongside eugenol and curcumin. FDA recognizes capsaicin as a counter-irritant in OTC topical analgesic products.
Volver